Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a phase 2 trial of monotherapy with the anti-CD38 monoclonal antibody, daratumumab, in patients with multiple myeloma who have received at least three different lines of therapy or who are double refractory.

Share this video  
12th June 2015